Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We previously reported gut dysbiosis in patients with Parkinson's disease (PD). OBJECTIVE: The aim of this study is to examine whether gut dysbiosis correlates with the progression of PD. METHODS: We examined changes in gut microbiota and demographic features in 2 years in 36 PD patients. RESULTS: A change of total UPDRS scores in 2 years was predicted by the counts of Bifidobacterium and Atopobium cluster at year 0 with a correlation coefficient of 0.52. Correlation analysis additionally revealed that low counts of Bifidobacterium and Bacteroides fragilis at year 0 were associated with worsening of UPDRS I scores in 2 years. In addition, low counts of Bifidobacterium at year 0 were associated with worsening of hallucinations/delusions in 2 years. Similarly, low counts of B. fragilis at year 0 were associated with worsening of motivation/initiative in 2 years. The patients were evenly divided into the deteriorated and stable groups based on the degree of worsening of total UPDRS scores. The deteriorated group had lower counts of Bifidobacterium, B. fragilis, and Clostridium leptium than the stable group at year 0 but not at year 2, suggesting that the deteriorated group may demonstrate accelerated lowering of these bacteria at year 0. CONCLUSIONS: The total counts of intestinal bacterial decrease in the course of PD progression. Temporal profiles of lowering of bacterial counts are likely to be different from bacteria to bacteria, and also between the deteriorating and stable groups, which may be able to be exploited to differentiate patients with rapidly and slowly progressive PD pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Minato et al. 57 investigated the relationship between intestinal disorders and disease progression through a 2-year follow-up of patients with Parkinson's disease and found that the decreased abundance of Bifidobacterium and Bacteroides fragilis was related to the deterioration of the Unified Parkinson's Disease Rating Scale (UPDRS)-I score”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [57]
The cited source says what the claim attributes to it.
In the citing paper
“suggesting that the gut microbiota may be seriously influenced by disease progression.57”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
(1996) · Institutional Research Information System University of Turin (University of Turin) · doi:10.1111/j · Cited by 5,486
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
The FAB: A frontal assessment battery at bedside
Dubois, B., Slachevsky, A., Litvan, I., & Pillon, B. (2000) · Neurology · doi:10.1212/wnl.55.11.1621 · Cited by 3,913
Gut Microbiota from Twins Discordant for Obesity Modulate Metabolism in Mice
Ridaura, V. K., Faith, J. J., Rey, F. E., Cheng, J., Duncan, A. E., Kau, A. L., Griffin, N. W., Lombard, V., Henrissat, B., Bain, J. R., et al. (2013) · Science · doi:10.1126/science.1241214 · Cited by 3,788
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Atopic Dermatitis: Global Epidemiology and Risk Factors
Nutten, S. (2015) · Annals of Nutrition and Metabolism · doi:10.1159/000370220 · Cited by 3,055
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Cited by
Items 101–200 of 258
The Gut‐Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications
Menozzi, E., Schapira, A. H. V., & Borghammer, P. (2025) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.70029 · Cited by 46
“105 In another study with mean follow-up of 2.25 years, no signi fi cant changes in gut microbiome structure were observed over time, however, the levels of genus Prevotella were found to be higher in stable PD patients compared with faster progressing at both baseline and follow-up, supporting a…”
InfluentialPapel de la microbiota intestinal en el desarrollo de diferentes enfermedades neurológicas
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2022) · Neurología · doi:10.1016/j.nrl.2019.03.017 · Cited by 37
Role of the gut microbiota in the development of various neurological diseases
Castillo-Álvarez, F., & Marzo-Sola, M. E. (2021) · Neurología (English Edition) · doi:10.1016/j.nrleng.2019.03.026 · Cited by 45
T cells, α-synuclein and Parkinson disease
Garretti, F., Monahan, C., Sette, A., Agalliu, D., & Sulzer, D. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00023-0 · Cited by 41
Adiponectin Role in Neurodegenerative Diseases: Focus on Nutrition Review
Polito, R., Meo, I. D., Barbieri, M., Daniele, A., Paolisso, G., & Rizzo, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239255 · Cited by 44
“Moreover, in PD patients, alterations in the gut microbiota are significantly associated with worsening of symptoms associated with PD [26].”
BackgroundDwyer, Z., Chaiquin, M., Landrigan, J., Ayoub, K., Shail, P., Rocha, J., Childers, C. L., Storey, K. B., Philpott, D. J., Sun, H., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02062-2 · Cited by 40
Gut Microbiota in Bone Health and Diabetes
Knudsen, J. K., Leutscher, P., & Sørensen, S. (2021) · Current Osteoporosis Reports · doi:10.1007/s11914-020-00629-9 · Cited by 42
Piancone, F., Saresella, M., Rosa, F. L., Marventano, I., Meloni, M., Navarro, J., & Clerici, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.639646 · Cited by 39
The neuromicrobiology of Parkinson’s disease: A unifying theory
Muñoz, M., Empadinhas, N., & Cardoso, S. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101396 · Cited by 39
“Another correlational study in PD patients revealed that erosion of Bifidobacterium spp. and Bacteroides fragilis was associated with worse Unified Parkinson’s Disease Rating Scale (UPDRS) scores (Minato et al., 2017).”
BackgroundFang, X., Liu, S., Muhammad, B., Zheng, M., Ge, X., Xu, Y., Shu, K., Zhang, Y., Yu, Y., Zheng, K., et al. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.391191 · Cited by 45
“Furthermore, a clinical study with 2-year follow-up indicated that decreased Bifidobacterium abundance in patients with PD correlates with worsening of PD symptoms (Minato et al., 2017).”
BackgroundGut Microbiota and Disorders of the Central Nervous System
Vuotto, C., Battistini, L., Caltagirone, C., & Borsellino, G. (2020) · The Neuroscientist · doi:10.1177/1073858420918826 · Cited by 37
Benefits of fecal microbiota transplantation: A comprehensive review
Ademe, M. (2020) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.12780 · Cited by 39
“However, in recent years, the existing evidences showed the interaction of dysbiotic gut with a wide range of disorders, including but not limited to cancer [31,32], obesity and diabetes mellitus [44], inflammatory bowel disease (IBD) [13], autism spectrum disorder [45], multiple sclerosis (MS) [46], atherosclerosis a…”
BackgroundBicknell, B. T., Liebert, A. D., McLachlan, C. S., & Kiat, H. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010049 · Cited by 38
“An earlier study on 36 PD sufferers [60], using real-time PCR rather than next generation sequencing, found that lower counts of Bifidobacterium, Bacteroides , and Clostridium cluster VI were associated with a more rapid deterioration.”
Efficacy and safety of probiotics in Parkinson’s constipation: A systematic review and meta-analysis
Xie, L., Chen, D., Xinghui, Z., & Cheng, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1007654 · Cited by 40
“Gut microbiota modulates the gut-brain axis interaction through the immune system, which is strongly associated with gastrointestinal symptoms that precede MSs, and is consistent with the hypothesis that PD pathology spreads from the gut to the brain (Mulak and Bonaz, 2015; Minato et al., 2017).”
BackgroundDeidda, G., & Biazzo, M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.753915 · Cited by 40
Chiu, L. S., & Anderton, R. S. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15892 · Cited by 37
A Novel Pathway for Microbial Metabolism of Levodopa
Jameson, K. G., & Hsiao, E. Y. (2019) · Nature Medicine · doi:10.1038/s41591-019-0544-x · Cited by 35
Jones, L., Kumar, J., Mistry, A., Sankar Chittoor Mana, T., Perry, G., Reddy, V. P., & Obrenovich, M. (2019) · Biomedicines · doi:10.3390/biomedicines7020024 · Cited by 34
“GPCRs, their cognate kinases and HDACs are implicated in the pathogenesis of neurodegenerative diseases [86,87].”
BackgroundIwaniak, P., Owe-Larsson, M., & Urbańska, E. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052915 · Cited by 34
Age-related diseases, therapies and gut microbiome: A new frontier for healthy aging
Barone, M., D’Amico, F., Rampelli, S., Brigidi, P., & Turroni, S. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111711 · Cited by 34
Singh, Y., El-Hadidi, M. S., Admard, J., Wassouf, Z., Schulze-Hentrich, J. M., Kohlhofer, U., Quintanilla‐Martínez, L., Huson, D. H., Rieß, O., & Casadei, N. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01032 · Cited by 35
Marć, M. A., Jastrząb, R., & Mytych, J. (2022) · Nutrients · doi:10.3390/nu14193967 · Cited by 36
Brain-gut-microbiota axis in Parkinson’s disease: A historical review and future perspective
Dong, S., Sun, M., He, C. H., & Cheng, H. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.015 · Cited by 34
Bi, M., Feng, L., He, J., Liu, C., Wang, Y., Jiang, H., & Liu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101759 · Cited by 34
Microbiome-based therapeutics for Parkinson's disease
Hamilton, A. M., Krout, I. N., White, A. C., & Sampson, T. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00462 · Cited by 33
Gut microbiota and Parkinson’s disease
Wang, L., Cui, Y., Han, B., Du, Y., Salewala, K. S., Wang, S., Zhao, W., Zhang, H., Wang, S., Xu, X., et al. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003318 · Cited by 38
Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
Palacios, N., Hannoun, A., Flahive, J., Ward, D., Goostrey, K., Deb, A., & Smith, K. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.574529 · Cited by 30
Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson’s Disease
Dănău, A., Dumitrescu, L., Lefter, A., Tulbă, D., & Popescu, B. O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111663 · Cited by 31
Microbiota Dysbiosis in Parkinson Disease—In Search of a Biomarker
Nowak, J. M., Kopczyński, M. H., Friedman, A., Koziorowski, D., & Figura, M. (2022) · Biomedicines · doi:10.3390/biomedicines10092057 · Cited by 32
“, 2017 [57] H&Y, UPRDS, LED 36 PD Bifidobacterium and Atopobium positively correlated with UPRDS”
MethodNielsen, S. D., Pearson, N. M., & Seidler, K. (2021) · Brain Research · doi:10.1016/j.brainres.2021.147609 · Cited by 37
Research Progress of Microbiota-Gut-Brain Axis in Parkinson's Disease
Zhang, W., Ye, Y., Song, J., Sang, T., Xia, T., Xie, L., Qiu, X., Zeng, Q., & Luo, X. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2206157 · Cited by 32
“Some studies suggest that PD patients may have consumed more milk than the general population since milk increases the number of gut Lactobacillus and Bifidobacterium strains which could increase the risk of PD [44], although it does not always show an increase [45].”
BackgroundKenyon, J., Coe, S., & Izadi, H. (2019) · Human Microbiome Journal · doi:10.1016/j.humic.2019.100061 · Cited by 28
“Recent research suggests that an altered microbiome may play a role in a wide range of disorders including Parkinson’s disease [22,23] chronic liver disease [24,25], myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) [26,27] and also impact cancer patient recovery after treatments such as chemotherapy and rad…”
BackgroundButy and the beast: the complex role of butyrate in Parkinson’s disease
Elford, J. D., Becht, N. N., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1388401 · Cited by 30
“…2015; Hill-Burns et al., 2017; Minato et al., 2017; Barichella et al., 2019; Nuzum et al., 2020; Romano et al., 2021; Papi ć et al., 2022; Takahashi et al., 2022) and in some studies were found to correlate with disease severity (Minato et al., 2017; Barichella et al., 2019; Baldini et al., 2020).”
BackgroundResultInfluentialFu, S., Shih, L.-C., Wu, P.-H., Hsieh, Y., Lee, C., Lin, S., & Wang, H. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.871710 · Cited by 29
Bai, H., Gu, H., Zhou, W., Shi, G., Yan, J., Su, Y., Li, W., Li, Y., Zhong, C., Zhao, N., et al. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.136974 · Cited by 29
A neuroscience perspective of the gut theory of Parkinson's disease
Smith, L. M., & Parr‐Brownlie, L. C. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13869 · Cited by 26
“disease continue after diagnosis and may be a biomarker of disease progression (Minato et al., 2017).”
BackgroundDrobny, A., Ngo, P. A., Neurath, M. F., Zunke, F., & López-Posadas, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655123 · Cited by 24
Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond
Brown, E. G., & Goldman, S. M. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00942-2 · Cited by 28
“To date, more than twenty cross-sectional studies have been published [22–42], of which two with longitudinal follow-up [43, 44].”
BackgroundRedox-related gaseous mediators in the gastrointestinal tract
Naito, Y., Uchiyama, K., & Takagi, T. (2018) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.18-56 · Cited by 24
Balakrishnan, R., Kang, S.-I., Lee, J. Y., Rho, Y., Kim, B.-K., & Choi, D. (2024) · Aging and Disease · doi:10.14336/ad.2024.1362 · Cited by 39
“…in SCFA profiles attributable to gut dysbiosis, diminished mucin synthesis, and enhanced bacterial or antigen translocation further propagate systemic inflammation and the activation of microglia or enteric glia, both of which have been implica ted in the misfolding of αSyn in PD models [122, 123].”
Cui, C., Shi, Y. W., Hong, H., Zhou, Y., Qiao, C.-M., Zhao, L., Jia, X.-B., Zhao, W., & Shen, Y. (2023) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-023-10085-8 · Cited by 25
“Low abundance of Bacteroides fragilis has been reported to associate with worsening of the Unified Parkinson’s Disease Rating Scale (UPDRS) I scores (Minato et al. 2017).”
Nunes, J. M., Fillis, T., PAge, M. J., Venter, C., Lancry, O., Kell, D. B., Windberger, U. B., & Pretorius, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01551 · Cited by 22
More than just a number: the gut microbiota and brain function across the extremes of life
Nuzum, N. D., Deady, C., Kittel‐Schneider, S., Cryan, J. F., O’Mahony, S. M., & Clarke, G. A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2418988 · Cited by 25
“10 Longitudinal research in PD and the gut microbiome has also now been conducted, 283–286 and research covering PD severity, 287 has begun to shed light on causality.”
Wang, S., Li, N., Zou, H.-X., & Wu, M. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.12.021 · Cited by 23
Mateo, D., Marquès, M., Domingo, J. L., & Torrente, M. (2023) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32959 · Cited by 20
“For example, low Bifidobacterium counts are associated with worse prognosis of hallucinations, while low Bacteroides counts are associated with motivational problems at 2-year follow-up (Minato et al., 2017).”
BackgroundZhao, R., Mu, B., Wang, D., XinHuang, Ma, Q., & Lu, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04584-9 · Cited by 29
“Prevotellaceae abundance has been reported to correlate significantly with PD severity score and UPDRS-III total score [17, 51] and decreases significantly with PD progression [52]; most studies have consistently reported a decrease in fecal Prevotellaceae in patients with PD [17–24].”
Hill, A. E., Wade‐Martins, R., & Burnet, P. W. J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708587 · Cited by 20
“Although two longitudinal studies have been conducted in PD patients, neither have reported significant changes in microbial composition with progression (Minato et al., 2017; Aho et al., 2019).”
BackgroundGut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease
Bolliri, C., Fontana, A., Cereda, E., Barichella, M., Cilia, R., Ferri, V., Caronni, S., Calandrella, D., Morelli, L., & Pezzoli, G. (2022) · Annals of Neurology · doi:10.1002/ana.26454 · Cited by 18
Defining Dysbiosis in Disorders of Movement and Motivation
Fields, C. T., Sampson, T. R., Bruce‐Keller, A. J., Kiraly, D. D., Hsiao, E. Y., & Vries, G. J. D. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1672-18.2018 · Cited by 21
Recent advances in understanding and treatment of Parkinson’s disease
Tarakad, A., & Jankovic, J. J. (2020) · Faculty Reviews · doi:10.12703/b/9-6 · Cited by 21
Cerroni, R., Pietrucci, D., Teofani, A., Chillemi, G., Liguori, C., Pierantozzi, M., Unida, V., Selmani, S., Mercuri, N. B., & Stefani, A. (2022) · Brain Sciences · doi:10.3390/brainsci12060739 · Cited by 18
“The main objective of our research was to demonstrate the stability of the microbiota composition over a short time and the reproducibility of the method of analysis; therefore, data from other longitudinal studies investigating disease progression related to microbiota changes are not comparable [40].”
MethodJi, T., Huang, H., Liu, J., Peng, T., Zhou, X., Tan, Q., Yuan, J., Hua, H., Ding, S., & Liu, H. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14952 · Cited by 17
“In particular, the abundance of Enterobacteriaceae is positively correlated with the severity of postural instability and gait difficulties in PD (Minato et al., 2017; Nagalingam, Kao, & Young, 2011; Scheperjans et al., 2015).”
BackgroundTsao, S., Yeh, T., Lin, Y., Pan, C., Lee, Y. K., Wu, C., & Huang, H.-Y. (2024) · Food & Function · doi:10.1039/d4fo02039a · Cited by 18
Abdurasulova, I. N., Тарасова, Е. А., Nikiforova, I. G., Ilves, A. G., Ивашкова, Е. В., Matsulevich, A. V., Tatarinov, A. E., Shangina, L. V., Ермоленко, Е. И., Клименко, В. М., et al. (2018) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201811808262 · Cited by 16
Zhang, P., Jin, W., Lyu, Z., Lyu, X., & Li, L. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.111001 · Cited by 17
“Levels of Bacteroides and Clostridium butyricum were displaying decreases as well as increases; Bifidobacteria and Lactobacilli , for example – the bacteria that produce SCFA – were found first to increase and then to decrease (Minato et al., 2017).”
BackgroundMild cognitive impairment and microbiota: what is known and future perspectives
Gallo, A., Martone, A. M., Liperoti, R., Cipriani, M. C., Ibba, F., Camilli, S., Rognoni, F. M., Landi, F., & Montalto, M. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1410246 · Cited by 15
“Although there is a general consensus about the relationship between gut microbiota and cognitive impairment in PD (36, 37, 49), there is also a study focused on comparison between gut microbiota composition in MCI and PD patients with a normal cognitive status.”
BackgroundRegulation of Pain Perception by Microbiota in Parkinson Disease
Manjarres, Z., Calvo, M., & Pacheco, R. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000674 · Cited by 15
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 18
“Over the past decade, numerous studies have reported associations between alterations in the gut microbiome and AD [341], Parkinson’s Disease [342], multiple sclerosis [343], and stroke [344].”
Do Bacterial Outer Membrane Vesicles Contribute to Chronic Inflammation in Parkinson’s Disease?
Koukoulis, T. F., Beauchamp, L. C., Kaparakis‐Liaskos, M., McQuade, R. M., Purnianto, A., Finkelstein, D. I., Barnham, K. J., & Vella, L. J. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230315 · Cited by 16
Manole, E., Dumitrescu, L., Niculite, C. M., Popescu, B. O., & Ceafalan, L. C. (2021) · Biocell · doi:10.32604/biocell.2021.013452 · Cited by 15
“, 2003) and presence of proinflammatory gut dysbiosis in people with PD, with increases in faecal Verrucomicrobiaceae and Akkermansia, which degrade the intestinal mucus layer, and decreases in the beneficial Prevotellaceae, Roseburia and Faecalibacterium being more consistently reported (Aho et al., 2019; Baldini et…”
BackgroundThe Pivotal Role of Microbiota in Modulating the Neuronal–Glial–Epithelial Unit
Luo, S., Zhu, H.-F., Zhang, J.-H., & Wan, D. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s342782 · Cited by 11
“Interestingly, a further study showed the total fecal bacterial counts decreased in all PD patients within 2 years, and the decreasing Bifidobacterium was associated with the progression of the disease.(55) Compared to wild-type, germ-free alphasynuclein-overexpressing (GF-ASO) mice exhibit a deficit in motor skills s…”
BackgroundGut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights
Guo, T., & Chen, L. (2022) · European Journal of Inflammation · doi:10.1177/1721727x221083763 · Cited by 14
Peter, I., & Strober, W. (2023) · Journal of Parkinson s Disease · doi:10.3233/jpd-230021 · Cited by 15
“fragilis and Bifidobacterium has been associated with worsening of motivation/initiative and hallucinations/delusions, respectively, using the Movement Disorder Society-United Parkinson’s Disease Rating Scale (MDS-UPDRS) scoring system [86], while the Clostridium coccoides and Lactobacillus gasseri species have report…”
MethodWeinberg, R. P., Koledova, V. V., Subramaniam, A., Schneider, K., Artamonova, A., Sambanthamurthi, R., Hayes, K. C., Sinskey, A. J., & Rha, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-54461-y · Cited by 16
Oral health implications in Parkinson’s disease
Qiu, X., Zhang, R., Cheng, Y., Jin, C., Zhang, Y., & Zhang, Z. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00927-y · Cited by 18
“Although PD patients generally have lower gut bacterial diversity compared to healthy individuals, absolute bacterial counts are often not reported, and bacterial levels tend to decline as PD progresses 61 .”
Is Gut Dysbiosis an Epicenter of Parkinson’s Disease?
Rajput, C., Sarkar, A., Sachan, N., Rawat, N., & Singh, M. P. (2021) · Neurochemical Research · doi:10.1007/s11064-020-03187-9 · Cited by 14
Gut Microbiota in Autophagy Regulation: New Therapeutic Perspective in Neurodegeneration
Mitra, S., Munni, Y. A., Dash, R., Sadhu, T., Barua, L., Islam, M. A., Chowdhury, D., Bhattacharjee, D., Mazumder, K., & Moon, I. S. (2023) · Life · doi:10.3390/life13040957 · Cited by 14
“PD patients were shown to have lower levels of SCFA-generating microbiota, such as Prevotellaceae and Lachnospiraceae, according to the investigations that were conducted in the past [133,134].”
BackgroundMutant and curli-producing E. coli enhance the disease phenotype in a hSOD1-G93A mouse model of ALS
Kurlawala, Z., McMillan, J. D., Singhal, R. A., Morehouse, J. R., Burke, D. A., Sears, S. M., Duregon, E., Beverly, L. J., Siskind, L. J., & Friedland, R. P. (2023) · Scientific Reports · doi:10.1038/s41598-023-32594-5 · Cited by 12
Pesticides and the Gut Microbiota: Implications for Parkinson’s Disease
Ghosh, N., Sinha, K., & Sil, P. C. (2024) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.4c00057 · Cited by 11
Moreno, L. O., Bagüés, A., Martínez, V., & Abalo, R. (2023) · Nutrients · doi:10.3390/nu15122775 · Cited by 11
Widjaja, F., & Rietjens, I. M. C. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102658 · Cited by 13
Hazan, S., Haroon, J. M., Jordan, S., & Walker, S. J. (2024) · Journal of Medical Cases · doi:10.14740/jmc4209 · Cited by 12
Small, S. L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102632 · Cited by 13
“…pathogenesis (Braak et al., 2006; Cersosimo and Benarroch, 2008), with some dysfunction in the gut-brain axis leading to misfolding of α -synuclein in the ENS (Bu et al., 2016; Mayer et al., 2015; Rhee et al., 2009; Shannon et al., 2012), contributing to disease progression (Minato et al., 2017).”
Gut Microbiota Dynamics in Parkinsonian Mice
Klann, E. M., Tagliamonte, M. S., Ukhanova, M., Mai, V., & Vedam‐Mai, V. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00386 · Cited by 10
Sharma, P., & Agrawal, A. (2021) · Neurosurgical Review · doi:10.1007/s10143-021-01516-2 · Cited by 11
“A study from Japan in 2017, took this association a step further by implicating a role of gut dysbiosis in disease progression in PD patients [65].”
BackgroundResultDoenyas, C. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01167-3 · Cited by 9
“Gut microflora dysbiosis has been implicated in neurobehavioral, neurodegenerative, and psychiatric conditions, such as anxiety, depression, autism spectrum disorder (ASD), Alzheimer’s disease (AD), multiple sclerosis, and Parkinson’s disease (Fung et al. 2017; Liu et al. 2020; Minato et al. 2017; Nishiwaki et al. 202…”
BackgroundThe effects of microbiota abundance on symptom severity in Parkinson’s disease: A systematic review
Papić, E., Rački, V., Hero, M., Tomić, Z., Čizmarević, N. S., Kovanda, A., Kapović, M., Hauser, G., Peterlin, B., & Vuletić, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1020172 · Cited by 10
“…abundance has also been found to have a positive Frontiers in Aging Neuroscience 12 frontiersin.org fnagi-14-1020172 December 2, 2022 Time: 14:34 # 13 Papić et al. 10.3389/fnagi.2022.1020172 correlation with UPDRS I scores, mainly through its link with hallucinations (Minato et al., 2017).”
BackgroundMethodInfluentialYeo, J. (2023) · Food Science and Biotechnology · doi:10.1007/s10068-023-01293-2 · Cited by 9
Buhmann, C., Ip, C. W., Oehlwein, C., Tönges, L., Wolz, M., Reichmann, H., & Kassubek, J. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0590-4464 · Cited by 9
Dopamine and Gastrointestinal Motility
Zheng, L., Liu, S., Zhou, L., Zhang, X., Xiao, Y., & Zhu, J. (2021) · Springer eBooks · doi:10.1007/978-981-33-6586-5_5 · Cited by 13
Disease mechanisms as subtypes: Microbiome
Bonvegna, S., & Cilia, R. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-85555-6.00006-0 · Cited by 8
Engineered nanomaterials and the microbiome: Implications for human health
Zickgraf, F. M., Murali, A., & Landsiedel, R. (2023) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2023.100429 · Cited by 9
Gut microbiota and parkinson's disease
Huarcaya, L. R. D., Mohammadi, M. R., & Ríos, M. F. D. (2021) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2021.410426.1165 · Cited by 7
“Based on our findings, it has been reported that the overall intestine bacterial count was lower in PD patients in comparison to healthy individuals [61].”
ResultDeciphering the microbial map and its implications in the therapeutics of neurodegenerative disorder
Vashishth, S., Ambasta, R. K., & Kumar, P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102466 · Cited by 9
Skonieczna‐Żydecka, K., Łoniewski, I., Maciejewska, D., & Marlicz, W. M. (2017) · Aktualności Neurologiczne · doi:10.15557/an.2017.0020 · Cited by 11
Ilie, O., Văcărean-Trandafir, I.-C., Amărandi, R.-M., Nita, I.-B., Dobrin, R., Doroftei, M., Ivanov, I.-C., Săvuţă, G., Kirov, B., & Doroftei, B. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1654995 · Cited by 7
The role of the gut microbiome in Parkinson’s disease
Metcalfe‐Roach, A., & Finlay, B. B. (2025) · Future Neurology · doi:10.1080/14796708.2025.2494981 · Cited by 6
Potential clinical usefulness of gut microbiome testing in a variety of clinical conditions
Morten, K., Staines-Urias, E., & Kenyon, J. (2018) · Human Microbiome Journal · doi:10.1016/j.humic.2018.08.003 · Cited by 6
“Recent research suggests that an altered microbiome may play a role in a wide range of disorders including Parkinson’s disease [22,23] chronic liver disease [24,25], myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) [26,27] and also impact cancer patient recovery after treatments such as chemotherapy and rad…”
BackgroundRethinking Parkinson Disease: Exploring Gut-Brain Interactions and the Potential Role of Exercise
Zapanta, K., Schroeder, E. T., & Fisher, B. E. (2022) · Physical Therapy · doi:10.1093/ptj/pzac022 · Cited by 5
LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
Menozzi, E., Macnaughtan, J., & Schapira, A. H. V. (2020) · Movement Disorders · doi:10.1002/mds.28347 · Cited by 5
“Although to date only 2 longitudinal studies have evaluated the relationship between microbiome composition and disease progression, it seems that some microbial features may differentiate between stable and faster progressors, suggesting a potential influence of the microbiome not only on disease onset but also on di…”
BackgroundNew Insights on the Role of Bioactive Food Derivatives in Neurodegeneration and Neuroprotection
Fisette, A., Sergi, D., Breton-Morin, A., Descôteaux, S., & Martinoli, M. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220919085742 · Cited by 6
Risk Factors of Parkinson’s Disease: A Case-Control Study in Moroccan Patients
Achbani, A., Ougjij, A. A., Wahmane, S. A., Sine, H., Kharbach, A., Bouchriti, Y., Belmouden, A., & Nejmeddine, M. (2022) · Archives of Neuroscience · doi:10.5812/ans-126351 · Cited by 5
“8 million in 2030 (7), possibly leading to an increase in the number of people with PD.”
BackgroundThe Association of the Oral Microbiota with Cognitive Functioning in Adolescence
Naumova, O. Y., Dobrynin, P. V., Khafizova, G. V., & Grigorenko, E. L. (2024) · Genes · doi:10.3390/genes15101263 · Cited by 4
“…microbiome, an increased presence of the Bifidobacterium genus has been negatively associated with cognitive function in late life and has been registered in participants with varying cognitive and depressive symptoms [62,69], AD and dementia [66,70,71], and deteriorated Parkinson’s disease [72].”
BackgroundWang, C., Tang, Y., Yang, T., Wang, Y., Niu, Z., Zhang, K., Lin, N., & Li, Q. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.16665 · Cited by 5
“Additionally, low levels of Bifidobacteria are associated with worsening hallucinations/delusions (Minato et al. 2017).”
Gut Microbiota and Aging: Targets and Anti-aging Interventions
Singh, B., Catanzaro, R., Mal, G., Gautam, S., Mohania, He, F., Yadav, H., Bissi, L., & Marotta, F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62181-5 · Cited by 4
Ko, Y., Kim, S., Pan, C., & Park, K. (2021) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2021.3100893 · Cited by 4
“Similarly, Bifidobacterium was known to aggravate PD symptoms even with a small population [60], and Oxalobacter showed a negative correlation with cognitive ability [61].”
BackgroundOnaolapo, A. Y., Ojo, F. O., Olofinnade, A. T., Falade, J., Lawal, I. A., & Onaolapo, O. J. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220903114559 · Cited by 5
El‐Mansoury, B., Smimih, K., Khiat, A. E., Fatimi, H. E., Aimrane, A., Baz, S. E., Elmourid, A., Saad, F. E.-Z., Ghachi, H. E., Khanouchi, M., et al. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5156-4.ch017 · Cited by 4
Wang, B., Geng, L., Wang, J., Wei, Y., Yan, C., Wu, N., Yue, Y., & Zhang, Q. (2024) · Marine Drugs · doi:10.3390/md22050193 · Cited by 5
Iyengar, A. S., Dunkley, P. R., & Dickson, P. W. (2025) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2025.578755 · Cited by 2
Metadata
- Authors
- Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M.
- Affiliations
- Nagoya University (JP)
- Iwate Medical University (JP)
- Yakult Central Institute (JP)
- Corresponding author
- Ohno, Kinji
- Hirayama, Masaaki
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-01
- Volume
- 12
- Issue
- 11
- Pages
- e0187307
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5665539
- OpenAlex
- W2766355490
- Cited by
- 248
- References
- 54
- Citations by year
- 2026: 11 · 2025: 9 · 2024: 27 · 2023: 29 · 2022: 40 · 2021: 42 · 2020: 37 · 2019: 33 · 2018: 19 · 2017: 1
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Update notices
- expression_of_concern (2023-01-11)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Japan Society for the Promotion of Science (JP) (24500458, 15H04840)
- Japan Agency for Medical Research and Development (JP) (17gm1010002h0002)
- Smoking Research Foundation (JP)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut dysbiosis, gut microbiota, disease progression, Unified Parkinson's Disease Rating Scale, Bifidobacterium, Bacteroides fragilis, Atopobium, delusions and hallucinations, motor symptoms, disease progression biomarkers
- MeSH terms
- Gastrointestinal Microbiome, Aged, Bacteroides fragilis, Bifidobacterium, Clostridium, Female, Follow-Up Studies, Humans, Male, Middle Aged, Parkinson Disease, Colony Count, Microbial, Disease Progression, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.